{
  "kind": "treatment",
  "slug": "lemborexant-dayvigo",
  "type": "sleep-medication",
  "name": "Lemborexant (Dayvigo)",
  "summary": "An orexin receptor antagonist used to treat insomnia characterized by difficulties with sleep onset and/or maintenance.",
  "description": "Lemborexant is a dual orexin receptor antagonist (DORA) that promotes sleep by inhibiting the wake-promoting neuropeptides orexin A and B from binding to their receptors (OX1R and OX2R). It is FDA-approved for the treatment of insomnia in adults, particularly for those with difficulty falling asleep and/or staying asleep.",
  "category": "medications/sleep-aids",
  "tags": [
    "insomnia",
    "orexin receptor antagonist",
    "sleep disorder"
  ],
  "metadata": {
    "drug_classes": [
      "Orexin Receptor Antagonist",
      "Hypnotic"
    ],
    "therapeutic_categories": [
      "Sleep Disorders"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": true,
    "generic_available": false,
    "brand_names": [
      "Dayvigo"
    ],
    "dea_schedule": "C-IV",
    "fda_pregnancy_category": "Not assigned",
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Sleep Medicine",
      "Psychiatry",
      "Primary Care"
    ],
    "fda_approval_year": 2019
  },
  "clinical_metadata": {
    "primary_indications": [
      "Insomnia"
    ],
    "off_label_uses": [],
    "contraindications": [
      "Narcolepsy",
      "Hypersensitivity to lemborexant or any ingredients"
    ],
    "monitoring_required": [
      "Daytime somnolence",
      "Complex sleep behaviors",
      "Depression or suicidal ideation"
    ],
    "efficacy_rating": {
      "sleep_onset": 4,
      "sleep_maintenance": 4,
      "overall_tolerability": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "lemborexant",
      "dayvigo",
      "orexin antagonist",
      "sleep medication",
      "insomnia"
    ],
    "synonyms": [],
    "common_misspellings": [
      "lamborexant",
      "lemborexan",
      "dayvego"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Insomnia characterized by difficulty with sleep onset and/or sleep maintenance"
      ]
    },
    {
      "type": "mechanism",
      "text": "Blocks orexin-1 and orexin-2 receptors, reducing the wake drive and promoting sleep."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "5 mg taken no more than once per night, immediately before bedtime with at least 7 hours remaining before planned awakening",
        "titrate": "If 5 mg is well tolerated but insufficient, increase to 10 mg nightly",
        "max": "10 mg once nightly"
      },
      "geriatric": "Start at 5 mg; use caution if increasing to 10 mg",
      "hepatic_impairment": "Avoid use in severe hepatic impairment; moderate impairment max 5 mg/night",
      "renal_impairment": "No dose adjustment required"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 5 mg, 10 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset within 30 minutes; half-life ~17â€“19 hours, enabling both sleep onset and maintenance effects."
    },
    {
      "type": "adverse_effects",
      "common": [
        "somnolence",
        "fatigue",
        "headache",
        "abnormal dreams"
      ],
      "less_common": [
        "sleep paralysis",
        "hypnagogic/hypnopompic hallucinations",
        "worsening depression"
      ],
      "serious": [
        "complex sleep behaviors (e.g., sleepwalking, sleep driving)",
        "suicidal ideation"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "Complex sleep behaviors can occur; discontinue if observed",
        "May cause next-day impairment, particularly at higher doses or without adequate sleep opportunity"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Strong CYP3A inhibitors",
          "risk": "Increased lemborexant exposure",
          "action": "Avoid combination"
        },
        {
          "with": "Strong or moderate CYP3A inducers",
          "risk": "Reduced efficacy",
          "action": "Avoid combination"
        },
        {
          "with": "Alcohol or CNS depressants",
          "risk": "Enhanced sedation",
          "action": "Use caution"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Daytime sleepiness",
        "Signs of depression or suicidality",
        "History of complex sleep behaviors"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Insufficient data; use only if benefits outweigh risks",
      "lactation": "Unknown if excreted in human milk; use caution",
      "pediatrics": "Not approved for use under 18 years",
      "geriatrics": "More sensitive to sedative effects; start low"
    },
    {
      "type": "tapering",
      "text": "No formal tapering needed, but abrupt discontinuation may cause rebound insomnia."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Similar mechanism to suvorexant but with slightly shorter half-life",
        "May be better tolerated in some patients due to reduced next-day grogginess compared to other hypnotics"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Dayvigo Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "American Academy of Sleep Medicine Guidelines",
          "url": "https://aasm.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Lemborexant (Dayvigo): Sleep Medication for Insomnia",
    "description": "Lemborexant (Dayvigo) is a dual orexin receptor antagonist for treating insomnia, improving both sleep onset and maintenance."
  }
}
